[go: up one dir, main page]

LT2959894T - S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui - Google Patents

S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui

Info

Publication number
LT2959894T
LT2959894T LTEP2959894T LT15177166T LT2959894T LT 2959894 T LT2959894 T LT 2959894T LT EP2959894 T LTEP2959894 T LT EP2959894T LT 15177166 T LT15177166 T LT 15177166T LT 2959894 T LT2959894 T LT 2959894T
Authority
LT
Lithuania
Prior art keywords
treatment
multiple sclerosis
receptor modulators
modulators
receptor
Prior art date
Application number
LTEP2959894T
Other languages
English (en)
Inventor
Peter C. Hiestand
Christian Schnell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888144&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2959894(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT2959894T publication Critical patent/LT2959894T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP2959894T 2006-06-27 2007-06-25 S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui LT2959894T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612721.1A GB0612721D0 (en) 2006-06-27 2006-06-27 Organic compounds

Publications (1)

Publication Number Publication Date
LT2959894T true LT2959894T (lt) 2022-11-10

Family

ID=36888144

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP2959894T LT2959894T (lt) 2006-06-27 2007-06-25 S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui

Country Status (21)

Country Link
US (3) US20100168078A1 (lt)
EP (4) EP2037906A1 (lt)
JP (8) JP2009541386A (lt)
KR (6) KR20150122812A (lt)
CN (2) CN101478961B (lt)
AU (7) AU2007264031C1 (lt)
BR (1) BRPI0713985A2 (lt)
CA (1) CA2653569C (lt)
DE (1) DE15177166T1 (lt)
DK (1) DK2959894T3 (lt)
ES (1) ES2887042T3 (lt)
GB (1) GB0612721D0 (lt)
HK (1) HK1214758A1 (lt)
HU (1) HUE059922T4 (lt)
LT (1) LT2959894T (lt)
MX (3) MX2008016133A (lt)
PL (1) PL2959894T3 (lt)
PT (1) PT2959894T (lt)
RU (1) RU2617502C2 (lt)
SI (1) SI2959894T1 (lt)
WO (1) WO2008000419A1 (lt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CN101674819A (zh) * 2007-05-04 2010-03-17 诺瓦提斯公司 S1p受体调节剂的用途
KR20180017232A (ko) * 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
KR101618906B1 (ko) 2008-08-18 2016-05-09 노파르티스 아게 말초 신경병증의 치료를 위한 화합물
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
CN102256941A (zh) * 2008-12-18 2011-11-23 诺瓦提斯公司 新的盐
JP5627597B2 (ja) * 2008-12-18 2014-11-19 ノバルティス アーゲー １−［４−［１−（４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ）−エチル］−２−エチル−ベンジル］−アゼチジン−３−カルボン酸ヘミフマル酸塩
KR20110112352A (ko) * 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
CN102712618B (zh) * 2009-11-24 2014-11-26 阿勒根公司 作为具有治疗效用的受体调节剂的新型化合物
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
JO3619B1 (ar) 2011-01-07 2020-08-27 Novartis Ag صياغات مثبطة للمناعة
CN102120720B (zh) * 2011-01-25 2013-05-22 上海华升生物科技有限公司 盐酸芬戈莫德的合成新方法
WO2013057212A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
JP6222081B2 (ja) * 2012-03-23 2017-11-01 日本電気株式会社 加入者サーバ、監視サーバ、移動端末、これらに関する方法、及びプログラム
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2023019320A1 (en) * 2021-08-20 2023-02-23 Carnegie Venture Capital Pty Ltd Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB612721A (en) 1946-02-11 1948-11-17 Richard William Bailey Improvements in combustion product power plant
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
EP1167384B1 (en) 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
USRE39072E1 (en) 1997-04-04 2006-04-18 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
CA2339961C (en) 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP1140173B2 (en) 1998-12-22 2013-04-03 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
PT1254138E (pt) 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
DE10033541C2 (de) 2000-07-11 2003-05-15 Litef Gmbh Lichtleitfaserspule für ein faseroptisches Sagnac-Interferometer und Verfahren zu ihrer Herstellung
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
RU2199339C2 (ru) 2001-02-23 2003-02-27 Общество с ограниченной ответственностью "Биотех" Способ лечения рассеянного склероза
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
CA2472713C (en) 2002-01-18 2011-07-19 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
DK1505959T3 (da) * 2002-05-16 2009-02-23 Novartis Ag Anvendelse af EDG-receptorbindingsmidler ved cancer
BR0311347A (pt) * 2002-05-27 2005-02-22 Novartis Ag Alcanóis bis-aromáticos
EP1575576A2 (en) * 2002-09-24 2005-09-21 Novartis AG Organic compounds
KR20040048231A (ko) * 2002-12-02 2004-06-07 주식회사 두산 신생혈관생성 억제제 및 그를 포함한 암 치료용 키트
FR2848495B1 (fr) * 2002-12-12 2006-11-17 Sidel Sa Four pour chauffer au defile des ebauches de recipients en materiau thermoplastique
PE20090743A1 (es) 2003-04-08 2009-07-17 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
BRPI0410746A (pt) * 2003-05-19 2006-06-27 Irm Llc compostos e composições imunossupressoras
EP2644195A1 (en) 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
MXPA06014421A (es) * 2004-06-10 2007-05-04 Regeneron Pharma Uso de inhibidores de vegf para el tratamiento de cancer humano.
CN102397542B (zh) * 2004-11-18 2014-05-07 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
BRPI0518105A (pt) * 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
RU2278687C1 (ru) 2005-06-16 2006-06-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ лечения ремиттирующего рассеянного склероза
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2633864A1 (en) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip inhibitors and methods of modulating immune function
GB2527550B (en) 2014-06-25 2016-09-21 Cook Medical Technologies Llc Implantable medical device with lumen constriction

Also Published As

Publication number Publication date
RU2617502C2 (ru) 2017-04-25
CN101478961B (zh) 2013-11-27
BRPI0713985A2 (pt) 2012-11-20
KR20210010956A (ko) 2021-01-28
DK2959894T1 (da) 2021-12-20
JP2019167352A (ja) 2019-10-03
AU2007264031B2 (en) 2011-01-27
KR20150122812A (ko) 2015-11-02
HUE15177166T1 (hu) 2022-05-28
JP7258832B2 (ja) 2023-04-17
AU2013200356A1 (en) 2013-02-14
MX2022008950A (es) 2022-08-11
CN103550195A (zh) 2014-02-05
HUE059922T2 (hu) 2023-01-28
JP2013166761A (ja) 2013-08-29
US9187405B2 (en) 2015-11-17
JP2021035955A (ja) 2021-03-04
HK1214758A1 (zh) 2016-08-05
KR20140069178A (ko) 2014-06-09
MX2008016133A (es) 2009-01-15
AU2011201844B2 (en) 2012-10-25
EP2698154A1 (en) 2014-02-19
JP2025016462A (ja) 2025-02-04
AU2007264031C1 (en) 2016-12-15
WO2008000419A1 (en) 2008-01-03
PT2959894T (pt) 2022-10-18
JP6931019B2 (ja) 2021-09-01
AU2018202210A1 (en) 2018-04-26
CN101478961A (zh) 2009-07-08
AU2021202395A1 (en) 2021-05-20
AU2007264031A1 (en) 2008-01-03
JP2009541386A (ja) 2009-11-26
US20100168078A1 (en) 2010-07-01
AU2019219818A1 (en) 2019-09-12
CA2653569A1 (en) 2008-01-03
US20140228446A1 (en) 2014-08-14
JP2016185957A (ja) 2016-10-27
KR20170138583A (ko) 2017-12-15
RU2569732C2 (ru) 2015-11-27
DE15177166T1 (de) 2022-01-27
AU2013200356B2 (en) 2016-09-29
DK2959894T3 (da) 2022-10-17
AU2011201844A1 (en) 2011-05-19
EP2959894A1 (en) 2015-12-30
PL2959894T3 (pl) 2022-11-14
JP2018109018A (ja) 2018-07-12
MX2019012750A (es) 2020-02-03
KR20090024281A (ko) 2009-03-06
EP2959894B1 (en) 2022-10-12
SI2959894T1 (sl) 2022-11-30
CA2653569C (en) 2016-06-21
KR20190030776A (ko) 2019-03-22
RU2009102278A (ru) 2010-08-10
EP2037906A1 (en) 2009-03-25
ES2887042T3 (es) 2022-11-14
EP3797765A1 (en) 2021-03-31
US8741963B2 (en) 2014-06-03
GB0612721D0 (en) 2006-08-09
US20110237682A1 (en) 2011-09-29
ES2887042T1 (es) 2021-12-21
AU2016266058A1 (en) 2016-12-22
HUE059922T4 (hu) 2024-05-28
RU2013131176A (ru) 2015-01-20
PL15177166T1 (pl) 2022-03-07
JP2023098949A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
LT2959894T (lt) S1p receptoriaus moduliatoriai, skirti išsėtinės sklerozės gydymui
CY2018004I1 (el) Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
HK1154206A1 (zh) 用於治療與其相關障礙的前列腺環素 受體調節器
DK2952177T3 (da) Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
DK3103448T3 (da) Farmaceutiske sammensætninger, der omfatter en S1P-modulator
EP2035369A4 (en) THERAPEUTIC COMPOUNDS
ITRE20060026A1 (it) Apparecchio per trattamenti medicinali
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
DK2144905T3 (da) Terapeutiske midler
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
DK2032551T3 (da) Antitumorale dihydropyran-2-on-forbindelser
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
DK2041128T3 (da) Substituerede gamma-lactamer som terapeutiske agenser
BRPI0716929A2 (pt) tratamento de esclerose méltipla com campath-1h
DK2310017T3 (da) Nifurtimox til behandling af sygdomme fremkaldt af trichomonadida
EP2079704A4 (en) THERAPEUTIC COMPOUNDS
BRPI0912193A2 (pt) compostos terapêuticos.
DK2379507T3 (da) Sulfonamidforbindelser til behandling af åndedrætsforstyrrelser
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
ES1062095Y (es) Dispositivo para la distribucion de medicamentos.